Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 12/20 | 0.35 |
| ▸ | MPEG1 | Q2M385 | 7/20 | 0.34 |
| ▸ | XIAP | P98170 | 2/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7295070 | 0.98 | HIF1A (0.43) | HIF1AEPAS1CA1CA9ACHE | |
| SCHEMBL9422903 | 0.98 | HIF1A (0.43) | HIF1AEPAS1CA1CA9ACHE | |
| SCHEMBL7303716 | 0.98 | HIF1A (0.43) | HIF1AEPAS1CA1CA9ACHE | |
| SCHEMBL18845026 | 0.86 | — | — | |
| SCHEMBL4530542 | 0.72 | ALOX5 (0.45) | CYP1A1PTPN1ALOX5MAPTPTGS2 | |
| SCHEMBL420617 | 0.69 | — | — | |
| SCHEMBL1021982 | 0.68 | ACHE (0.40) | ACHEBACE1ALOX5MPEG1GPR84 | |
| SCHEMBL24849580 | 0.68 | PDCD4 (0.39) | CA1CA9ACHEBACE1GPR84 | |
| SCHEMBL7296440 | 0.67 | PDCD4 (0.41) | GPR84DUSP3 | |
| SCHEMBL4867436 | 0.67 | ACHE (0.43) | ACHEBACE1ALOX5MPEG1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11957657-B2 | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230390241-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-12-07 | — | — | US | disclosed |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-02-21 | — | — | US | disclosed |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2023-01-24 | — | — | US | disclosed |
| US-20200054655-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2020-02-20 | — | — | US | disclosed |
| EP-3509604-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | Trustees of Tufts College (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20190209525-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2019-07-11 | — | — | US | disclosed |
| WO-2018187698-A2 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE (US) | 2018-10-11 | — | — | WO | disclosed |
| WO-2018049008-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20030114416-A1 | Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate | PHARMACIA CORPORATION | 2003-06-19 | — | — | US | disclosed |
| US-20030114418-A1 | Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor | PHARMACIA CORPORATION | 2003-06-19 | — | — | US | disclosed |
| WO-2003015797-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND GLUCOSAMINE | PHARMACIA CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003015799-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND CHONDROITIN SULFATE | PHARMACIA CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1017687-A4 | PROCESS OF MAKING 3-ARYLOXY, 4-ARYL FURAN-2-ONES USEFUL AS INHIBITORS OF COX-2 | MERCK & CO INC (US) | 2001-10-31 | — | — | EP | disclosed |
| US-6140515-A | Process of making 3-aryloxy, 4-aryl furan-2-ones useful as inhibitors of COX-2 | MERCK & CO., INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-6140515-A | Process of making 3-aryloxy, 4-aryl furan-2-ones useful as inhibitors of COX-2 | MERCK & CO., INC. (US) | 2000-10-31 | — | — | US | disclosed |
| EP-1017687-A1 | PROCESS OF MAKING 3-ARYLOXY, 4-ARYL FURAN-2-ONES USEFUL AS INHIBITORS OF COX-2 | Merck & Co., Inc. (US) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999015513-A1 | PROCESS OF MAKING 3-ARYLOXY, 4-ARYL FURAN-2-ONES USEFUL AS INHIBITORS OF COX-2 | MERCK & CO., INC. (US) | 1999-04-01 | — | — | WO | disclosed |
| US-4265903-A | HYPOTENSIVE, ADRENOLYTIC | BEIERSDORF AKTIENGESELLSCHAFT (DE) | 1981-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390241-A1 | DASH INHIBITORS, AND USES RELATED THERETO | CD2BP2, PCNA, CD2 | HIF1A 2559/4885EPAS1 353/4885CA1 4492/4885 |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | PCNA, CD2BP2, CCNO | HIF1A 2633/4885EPAS1 400/4885CA1 4342/4885 |
| US-20030114416-A1 | Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate | CSGALNACT1, PTGS2, PTGS1 | HIF1A 1167/4885EPAS1 3011/4885CA1 577/4885 |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | CASP1, CASP2, APAF1 | HIF1A 808/4885EPAS1 282/4885CA1 957/4885 |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | HIF1A 808/4885EPAS1 282/4885CA1 957/4885 |
| US-11957657-B2 | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | HPGDS, PTGIS, PTGDR2 | HIF1A 2871/4885EPAS1 9/4885CA1 4702/4885 |
| US-20200054655-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | HIF1A 808/4885EPAS1 282/4885CA1 957/4885 |
| US-20030114418-A1 | Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor | PTGS2, PTGS1, UGGT1 | HIF1A 1071/4885EPAS1 2260/4885CA1 2337/4885 |
| US-20190209525-A1 | DASH INHIBITORS, AND USES RELATED THERETO | CD2BP2, PCNA, CD2 | HIF1A 2559/4885EPAS1 353/4885CA1 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.